Empagliflozin for weight and metabolism in HIV
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Infections clinical trials.
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your body mass index (BMI) is over 30, meaning you are in the obese range.
- You take a dolutegravir-based HIV medication (an INSTI regimen).
- Your HIV is well-controlled: viral load under 200 copies/mL for at least 6 months and CD4 count above 250.
- You do not have diabetes, significant kidney problems, active hepatitis B or C, or a known thyroid disorder.
- You are not taking other SGLT-2 inhibitors or medications that interact with empagliflozin or dolutegravir.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This study tests whether a diabetes medication called an SGLT2 inhibitor can reduce inflammation in body fat and improve blood vessel function in people with metabolic syndrome. It may help prevent heart disease and other complications.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This study compares two diabetes medications, dapagliflozin and empagliflozin, to see which is more effective, safe, and affordable for people with type 2 diabetes and a high body weight. Both medications help lower blood sugar and may also help with weight loss.
This study tests a very low dose of a medication called a GLP-1 receptor agonist to see if it can improve heart and metabolic health in people with HIV who have excess weight.
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.